Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Recruiting · NCT06447376 · Registry updated 2026-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab | Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-06-25 | NCT06447376 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Genmab | 54 |
| RECORDATI GROUP | 16 |
| Taylor Brooks | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | Cleveland | United States | 20 |